GB1560232A - Biphasic insulin preparations comprising crystalline insulin and monodesamido insulin - Google Patents
Biphasic insulin preparations comprising crystalline insulin and monodesamido insulin Download PDFInfo
- Publication number
- GB1560232A GB1560232A GB4121/77A GB412177A GB1560232A GB 1560232 A GB1560232 A GB 1560232A GB 4121/77 A GB4121/77 A GB 4121/77A GB 412177 A GB412177 A GB 412177A GB 1560232 A GB1560232 A GB 1560232A
- Authority
- GB
- United Kingdom
- Prior art keywords
- insulin
- preparation
- solution
- zinc
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 321
- 229940125396 insulin Drugs 0.000 title claims abstract description 164
- 108090001061 Insulin Proteins 0.000 title claims abstract description 154
- 102000004877 Insulin Human genes 0.000 title claims abstract description 154
- 238000002360 preparation method Methods 0.000 title claims abstract description 107
- 108010065691 Biphasic Insulins Proteins 0.000 title claims description 11
- 239000000189 biphasic insulin Substances 0.000 title claims description 11
- 239000000725 suspension Substances 0.000 claims abstract description 54
- 239000011701 zinc Substances 0.000 claims abstract description 38
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 37
- 230000002051 biphasic effect Effects 0.000 claims abstract description 19
- 239000012736 aqueous medium Substances 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 84
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 31
- 239000013078 crystal Substances 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 22
- 241000283690 Bos taurus Species 0.000 claims description 19
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 108010005991 Pork Regular Insulin Proteins 0.000 claims description 13
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 239000004246 zinc acetate Substances 0.000 claims description 12
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 10
- 239000001632 sodium acetate Substances 0.000 claims description 10
- 235000017281 sodium acetate Nutrition 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 6
- 239000011592 zinc chloride Substances 0.000 claims description 6
- 235000005074 zinc chloride Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 101001011741 Bos taurus Insulin Proteins 0.000 description 14
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000005518 carboxamido group Chemical group 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 108700022849 desamido- insulin Proteins 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- -1 sodium chloride Chemical class 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DTYKTFHKOAPBCJ-UHFFFAOYSA-N ethylaminomethanol Chemical compound CCNCO DTYKTFHKOAPBCJ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4121/77A GB1560232A (en) | 1977-02-01 | 1977-02-01 | Biphasic insulin preparations comprising crystalline insulin and monodesamido insulin |
| AU32754/78A AU503013B1 (en) | 1977-02-01 | 1978-01-26 | Injectable biphasic zinc-containing insulin preparation |
| ES466477A ES466477A1 (es) | 1977-02-01 | 1978-01-30 | Procedimiento para la obtencion de una preparacion inyecta- ble bifasica de insulina |
| FR7802582A FR2378516A1 (fr) | 1977-02-01 | 1978-01-30 | Nouvelles preparations injectables d'insuline biphasee et procede pour obtention |
| DK44478A DK149322C (da) | 1977-02-01 | 1978-01-31 | Fremgangsmaade til fremstilling af et stabilt, injicerbart, tofasisk, zinkholdigt insulinpraeparat |
| DE19782803996 DE2803996A1 (de) | 1977-02-01 | 1978-01-31 | Zweiphasiges insulinpraeparat und verfahren zu seiner herstellung |
| SE7801163A SE445887B (sv) | 1977-02-01 | 1978-01-31 | Forfarande for framstellning av ett stabilt, injicerbart, zinkhaltigt insulinpreparat av tvafastyp |
| CA295,949A CA1099632A (en) | 1977-02-01 | 1978-01-31 | Biphasic insulin preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4121/77A GB1560232A (en) | 1977-02-01 | 1977-02-01 | Biphasic insulin preparations comprising crystalline insulin and monodesamido insulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1560232A true GB1560232A (en) | 1980-01-30 |
Family
ID=9771155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB4121/77A Expired GB1560232A (en) | 1977-02-01 | 1977-02-01 | Biphasic insulin preparations comprising crystalline insulin and monodesamido insulin |
Country Status (6)
| Country | Link |
|---|---|
| AU (1) | AU503013B1 (enExample) |
| CA (1) | CA1099632A (enExample) |
| DE (1) | DE2803996A1 (enExample) |
| FR (1) | FR2378516A1 (enExample) |
| GB (1) | GB1560232A (enExample) |
| SE (1) | SE445887B (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657425A (en) * | 1969-03-12 | 1972-04-18 | Burroughs Wellcome Co | Beef insulin preparations |
| EG12098A (en) * | 1974-04-13 | 1980-12-31 | Hoechst Ag | New pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture |
-
1977
- 1977-02-01 GB GB4121/77A patent/GB1560232A/en not_active Expired
-
1978
- 1978-01-26 AU AU32754/78A patent/AU503013B1/en not_active Expired
- 1978-01-30 FR FR7802582A patent/FR2378516A1/fr active Granted
- 1978-01-31 DE DE19782803996 patent/DE2803996A1/de not_active Ceased
- 1978-01-31 CA CA295,949A patent/CA1099632A/en not_active Expired
- 1978-01-31 SE SE7801163A patent/SE445887B/sv unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU503013B1 (en) | 1979-08-16 |
| FR2378516B1 (enExample) | 1982-04-23 |
| DE2803996A1 (de) | 1978-11-09 |
| SE7801163L (sv) | 1978-08-02 |
| SE445887B (sv) | 1986-07-28 |
| CA1099632A (en) | 1981-04-21 |
| FR2378516A1 (fr) | 1978-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5898067A (en) | Crystallization of proteins | |
| DE3687500T2 (de) | Insulinabkoemmlinge und arzneimittel die diese enthalten. | |
| DE3750897T2 (de) | Verfahren für Umwandlung von menschlichem Insulin-Vorläufer in menschliches Insulin. | |
| EP0368187B1 (de) | Neue Insulinderivate, ihre Verwendung und eine sie enthaltende pharmazeutische Zubereitung | |
| EP0305760B1 (de) | Verfahren zur Isolierung basischer Proteine aus Proteingemischen | |
| DE3104949A1 (de) | Verfahren zur herstellung von threonin(pfeil hoch)b(pfeil hoch)(pfeil hoch)3(pfeil hoch)(pfeil hoch)0(pfeil hoch)-estern menschlichen insulins sowie threonin(pfeil hoch)b(pfeil hoch)(pfeil hoch)3(pfeil hoch)(pfeil hoch)0(pfeil hoch)-ester menschlichen insulins | |
| DE3048612C2 (de) | "Verfahren zur enzymatischen Trennung von L-2-Ami no-4-methylphosphinobuttersäure" | |
| DE2440529A1 (de) | Hyaluronidase-proeparat aus menschlicher plazenta und verfahren zu seiner gewinnung | |
| DE3229674C2 (enExample) | ||
| Rucker et al. | Properties of chick tropoelastin | |
| DE3936876A1 (de) | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung | |
| EP0135720B1 (de) | Verfahren zur Herstellung von Insulin-Derivaten | |
| EP0013826A1 (en) | Process for purifying insulin and insulin so prepared | |
| CA1155439A (en) | Insulin crystal suspension and process for the preparation thereof | |
| EP0966482B1 (en) | Crystallisation of proteins | |
| CA1099632A (en) | Biphasic insulin preparations | |
| EP0622376B1 (de) | Amorphe monosphärische Formen von Insulinderivaten | |
| DE2825289A1 (de) | 1-n-(omega-aminoalkansulfonyl)-derivate von aminoglycosidischen antibiotika und verfahren zur herstellung derselben | |
| EP0180859B1 (de) | Verfahren zur Reinigung sowie Pasteurisierung von Urokinase | |
| EP0087238A1 (en) | Am improved method for preparing human insulin from non-human insulin | |
| DD157613A5 (de) | Verfahren zur herstellung eines insulins oder insulinanalogs | |
| DE3511270A1 (de) | Insulin aus pankreasextrakten | |
| EP0219839A2 (de) | Derivat des Interleukin-2, seine Herstellung und Verwendung | |
| IE40985B1 (en) | Insulin preparations having antidiabetic activity and process for their manufacture | |
| DE1966573B2 (de) | Verfahren zur Reinigung von Insulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 416 | Proceeding under section 16 patents act 1949 | ||
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |